![](https://endpts.com/wp-content/uploads/2021/08/Christian-Itin-Autolus-UKBIO19-tile-scaled.jpg)
Christian Itin, Autolus CEO (UKBIO19)
Autolus eyes November for potential US approval of Tecartus rival
Autolus Therapeutics is expecting an FDA decision on Nov. 16 for obecabtagene autoleucel (obe-cel), its CAR-T hopeful that would rival Gilead’s Tecartus in adult acute …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.